See more : Fortum Oyj (FOJCY) Income Statement Analysis – Financial Results
Complete financial analysis of Fortress Biotech, Inc. (FBIOP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fortress Biotech, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Anderson Industrial Corporation (1528.TW) Income Statement Analysis – Financial Results
- Prataap Snacks Limited (DIAMONDYD.NS) Income Statement Analysis – Financial Results
- Hu Lane Associate Inc. (6279.TWO) Income Statement Analysis – Financial Results
- Accor Acquisition Company S.A. (AAC.PA) Income Statement Analysis – Financial Results
- Stagwell Inc. (STGW) Income Statement Analysis – Financial Results
Fortress Biotech, Inc. (FBIOP)
About Fortress Biotech, Inc.
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 84.51M | 75.74M | 68.79M | 45.60M | 36.63M | 26.88M | 187.58M | 16.48M | 863.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 26.66M | 30.78M | 32.08M | 14.59M | 10.53M | 6.13M | 161.20M | 11.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 57.85M | 44.97M | 36.71M | 31.01M | 26.10M | 20.76M | 26.38M | 5.13M | 863.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit Ratio | 68.45% | 59.37% | 53.36% | 67.99% | 71.25% | 77.22% | 14.06% | 31.13% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 106.07M | 134.88M | 128.87M | 64.11M | 81.33M | 87.38M | 52.49M | 35.13M | 29.81M | 10.24M | 25.68M | 18.51M | 29.29M | 8.34M |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 55.59M | 53.37M | 73.02M | 35.16M | 21.58M | 10.41M | 10.10M | 8.67M | 5.76M | 900.00K |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 155.19M | 10.41M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 94.12M | 113.66M | 86.84M | 61.17M | 55.59M | 53.37M | 73.02M | 35.16M | 21.58M | 10.41M | 10.10M | 8.67M | 5.76M | 900.00K |
Other Expenses | 0.00 | -1.30M | 25.17M | 2.83M | 6.09M | 68.00K | -234.00K | -9.87M | 11.41M | 0.00 | 0.00 | 0.00 | 5.76M | 733.00K |
Operating Expenses | 200.20M | 247.23M | 215.71M | 125.28M | 136.92M | 140.75M | 127.59M | 70.84M | 51.39M | 20.65M | 35.78M | 27.18M | 35.04M | 9.24M |
Cost & Expenses | 226.86M | 278.00M | 247.79M | 139.87M | 147.45M | 146.88M | 288.79M | 82.19M | 51.39M | 20.65M | 35.78M | 27.18M | 35.04M | 9.24M |
Interest Income | 3.00M | 1.40M | 649.00K | 1.52M | 2.56M | 1.10M | 819.00K | 298.00K | 245.00K | 662.00K | 545.00K | 236.00K | 165.00K | 61.00K |
Interest Expense | 11.92M | 13.64M | 15.31M | 9.70M | 11.85M | 10.34M | 5.86M | 3.69M | 1.48M | 1.34M | 1.90M | 670.00K | 74.00K | 313.00K |
Depreciation & Amortization | 8.07M | 9.35M | 6.79M | 5.33M | 4.65M | 2.06M | 1.26M | 728.00K | 26.00K | 23.00K | 17.00K | 3.00K | 1.41M | 5.00K |
EBITDA | -133.64M | -190.47M | -142.25M | -87.82M | -85.16M | -118.40M | -88.57M | -66.87M | -52.37M | -20.63M | -35.76M | -27.18M | -35.04M | -8.45M |
EBITDA Ratio | -158.13% | -265.19% | -259.27% | -204.06% | -282.85% | -434.37% | -52.53% | -390.08% | -5,826.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -142.34M | -202.26M | -179.00M | -94.27M | -110.82M | -120.00M | -101.21M | -65.71M | -50.53M | -20.65M | -35.78M | -27.18M | -35.04M | -9.24M |
Operating Income Ratio | -168.43% | -267.03% | -260.21% | -206.74% | -302.54% | -446.38% | -53.95% | -398.73% | -5,855.27% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | -11.29M | -9.90M | 24.19M | -8.58M | 9.16M | -10.80M | -7.72M | -5.58M | -3.35M | 266.00K | -1.38M | -434.00K | -1.32M | -741.00K |
Income Before Tax | -153.63M | -213.46M | -164.35M | -102.85M | -101.66M | -130.80M | -98.32M | -71.29M | -53.88M | -20.39M | -37.16M | -27.61M | -36.36M | -9.98M |
Income Before Tax Ratio | -181.79% | -281.83% | -238.92% | -225.55% | -277.54% | -486.57% | -52.42% | -432.58% | -6,243.68% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 521.00K | 449.00K | 473.00K | 136.00K | -49.85M | -463.00K | 1.51M | -12.51M | -4.00M | 1.32M | 525.00K | 233.00K | -91.00K | 1.05M |
Net Income | -60.64M | -213.91M | -164.83M | -102.99M | -51.81M | -84.15M | -66.88M | -55.10M | -48.43M | -20.39M | -37.16M | -27.61M | -36.36M | -9.98M |
Net Income Ratio | -71.75% | -282.42% | -239.60% | -225.85% | -141.44% | -313.02% | -35.65% | -334.31% | -5,611.59% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -8.47 | -36.10 | -30.26 | -21.45 | -14.20 | -29.04 | -24.08 | -20.68 | -18.56 | -8.42 | -18.32 | -19.12 | -4.74 | -1.69 |
EPS Diluted | -8.47 | -36.10 | -30.26 | -21.45 | -14.20 | -29.04 | -24.08 | -20.68 | -18.56 | -8.42 | -18.32 | -19.12 | -4.74 | -1.69 |
Weighted Avg Shares Out | 8.11M | 5.92M | 5.45M | 4.80M | 3.65M | 2.90M | 2.78M | 2.66M | 2.61M | 2.42M | 2.03M | 1.44M | 7.66M | 5.90M |
Weighted Avg Shares Out (Dil) | 8.11M | 5.92M | 5.45M | 4.80M | 3.65M | 2.90M | 2.78M | 2.66M | 2.61M | 2.42M | 2.03M | 1.44M | 7.66M | 5.90M |
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Fortress Biotech to Participate in October 2024 Investor Conferences
Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements
Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027
Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
Fortress Biotech, Inc. (FBIO) Q3 2022 Earnings Call Transcript
Journey Medical Corporation (FBIO) CEO Claude Maraoui on Q2 2022 Results - Earnings Call Transcript
Fortress Biotech (FBIO) Investor Presentation - Slideshow
Source: https://incomestatements.info
Category: Stock Reports